SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.809
AS - Asia 7.677
EU - Europa 4.041
SA - Sud America 1.411
AF - Africa 193
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 9
Totale 27.153
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.555
SG - Singapore 3.332
CN - Cina 1.484
PL - Polonia 1.294
BR - Brasile 1.150
VN - Vietnam 847
HK - Hong Kong 712
IT - Italia 561
DE - Germania 386
TR - Turchia 361
GB - Regno Unito 336
UA - Ucraina 327
SE - Svezia 277
RU - Federazione Russa 215
FR - Francia 201
IN - India 153
JP - Giappone 147
ID - Indonesia 136
AR - Argentina 108
MX - Messico 107
CA - Canada 104
BD - Bangladesh 97
NL - Olanda 88
FI - Finlandia 86
ZA - Sudafrica 75
IQ - Iraq 67
IE - Irlanda 53
PK - Pakistan 44
AT - Austria 41
ES - Italia 37
JO - Giordania 35
EC - Ecuador 34
VE - Venezuela 32
KR - Corea 31
CO - Colombia 28
MA - Marocco 27
SA - Arabia Saudita 27
PH - Filippine 26
BE - Belgio 23
AE - Emirati Arabi Uniti 22
TN - Tunisia 22
MY - Malesia 20
CL - Cile 19
UZ - Uzbekistan 17
RO - Romania 14
DZ - Algeria 13
AU - Australia 12
EG - Egitto 12
AL - Albania 11
AZ - Azerbaigian 11
ET - Etiopia 11
NP - Nepal 11
CH - Svizzera 10
IR - Iran 10
KE - Kenya 10
LT - Lituania 10
PE - Perù 10
PT - Portogallo 10
BO - Bolivia 9
JM - Giamaica 9
PY - Paraguay 9
LB - Libano 8
OM - Oman 8
BG - Bulgaria 7
CZ - Repubblica Ceca 7
GE - Georgia 7
IL - Israele 7
KG - Kirghizistan 7
PS - Palestinian Territory 7
RS - Serbia 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
GR - Grecia 6
MD - Moldavia 6
SC - Seychelles 6
UY - Uruguay 6
XK - ???statistics.table.value.countryCode.XK??? 6
BH - Bahrain 5
KZ - Kazakistan 5
TH - Thailandia 5
TW - Taiwan 5
AO - Angola 4
DK - Danimarca 4
KH - Cambogia 4
LV - Lettonia 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
CY - Cipro 3
GA - Gabon 3
GY - Guiana 3
HN - Honduras 3
HR - Croazia 3
NI - Nicaragua 3
QA - Qatar 3
SY - Repubblica araba siriana 3
EU - Europa 2
GD - Grenada 2
Totale 27.116
Salva come PNG Salva come JPEG
Città #
Singapore 1.942
Ashburn 1.603
Fairfield 1.499
Warsaw 1.289
Woodbridge 1.181
San Jose 926
Houston 765
Hong Kong 699
Seattle 614
Santa Clara 593
Chandler 551
Wilmington 496
Jacksonville 495
Cambridge 486
Beijing 390
Ann Arbor 380
Izmir 300
Ho Chi Minh City 282
Dallas 258
Los Angeles 183
Princeton 183
Hanoi 182
Nanjing 170
Lauterbourg 154
Tokyo 144
Milan 136
São Paulo 113
Jakarta 109
The Dalles 109
San Diego 106
Boardman 104
Council Bluffs 99
New York 99
Columbus 97
Dearborn 94
Dong Ket 82
Helsinki 74
London 74
Menlo Park 69
Mexico City 68
Moscow 68
Nanchang 68
Chicago 54
Ferrara 53
Tianjin 47
Orem 46
Hebei 45
Falls Church 42
Bologna 41
Shanghai 41
Rio de Janeiro 38
Shenyang 38
Buffalo 36
Brooklyn 34
Mountain View 34
Toronto 33
Da Nang 32
Haiphong 32
Atlanta 31
Munich 31
Nuremberg 31
Johannesburg 30
Phoenix 30
Baghdad 29
Boston 28
San Francisco 28
Denver 27
Montreal 27
Belo Horizonte 26
Changsha 26
Jiaxing 25
Rome 25
Stockholm 25
Frankfurt am Main 24
Kunming 24
Redwood City 24
Washington 24
Biên Hòa 22
Brussels 22
Manchester 22
Norwalk 22
Vienna 22
Brasília 20
Poplar 20
Chennai 19
Curitiba 19
Orange 19
Amsterdam 18
Dhaka 18
Hangzhou 17
Hải Dương 17
Porto Alegre 17
Scottsdale 16
Guangzhou 15
Jinan 15
Tashkent 15
Amman 14
Fuzhou 14
Mumbai 14
Addison 13
Totale 18.905
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 534
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 379
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 296
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 283
Development of sentinel node localization and ROLL in breast cancer in Europe 275
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 275
A novel radioguided surgery technique exploiting β- decays 274
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 267
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 254
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 252
Early use of abiraterone and radium-223 in metastatic prostate cancer 244
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 241
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 238
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 236
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 226
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 221
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 216
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 216
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 214
A parathyroid carcinoma within a cold thyroid nodule 208
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 208
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 207
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 207
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 207
Radioimmunotherapy in brain tumors 204
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 202
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 201
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 200
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 199
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 191
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 190
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 190
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 188
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 186
[18 f]f-psma-1007 radiolabelling without an on-site cyclotron: A quality issue 186
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 184
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 182
Yttrium-labelled peptides for therapy of NET 180
177Lu specific activity influence over DOTATATE radiolabeling: experimental data 179
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 179
A delphic consensus assessment: Imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 178
Neuroendocrine tumors 175
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 175
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 173
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 169
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 168
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 168
Sentinel lymph node biopsy in pregnant patients with breast cancer 166
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 166
Dosimetry for treatment with radiolabelled somatostatin analogues. A review 166
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 165
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 165
Financial aspects of sentinel lymph node biopsy in early breast cancer 165
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 164
Long-term results of PRRT in advanced bronchopulmonary carcinoid 164
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 164
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 163
Yttrium-based therapy for neuroendocrine tumors 162
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 162
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 162
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 160
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 159
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 158
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 158
Positron emission tomography for the detection of colorectal adenomas 158
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 158
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 157
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 156
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 156
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 156
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 156
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors 156
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 155
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 154
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 154
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 154
Erratum: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 153
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 152
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 151
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 150
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 150
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 150
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 149
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 147
OXavidin for tissue targeting biotinylated therapeutics 147
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 147
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 147
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 147
PET/CT and breast cancer subtypes 146
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients 146
CAR-T cell therapy: A potential new strategy against prostate cancer 146
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review 145
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 144
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 144
Quantitative accuracy of177Lu SPECT imaging for molecular radiotherapy 144
Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting 144
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 141
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 141
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide 141
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen) 141
Totale 18.577
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.783
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 4.648
Totale 142.431
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021438 0 0 0 0 0 0 0 0 0 0 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20254.132 58 97 333 157 510 407 151 253 697 608 646 215
2025/20269.821 862 523 1.044 1.089 1.532 610 1.343 599 1.031 1.181 7 0
Totale 27.697